The greatest development challenge emerging for many PROTAC programs is generating reliable absorption, distribution, metabolism, and excretion (ADME) data. Standard workflows developed for conventional small molecules often produce misleading or low-confidence results when applied to targeted protein degraders, creating significant risk during candidate selection and optimization.
Traditional ADME workflows were largely developed around orally bioavailable small molecules that conform to Lipinski’s Rule of Five. The behavior of PROTACs, by contrast, frequently extends beyond these boundaries, often yielding misleading or low-confidence data when analyzed with standard, unmodified assays. As a result, assay design that strategically responds to a few key distinguishing characteristics of PROTACS has become a critical determinant of data quality and translational relevance in their development.
PROTACS Blur the Boundaries Between Modalities
Many conventional developability assumptions break down when applied to PROTACs. PROTACs commonly exceed common molecular weights of traditional small molecules while exhibiting high LogP values and substantial molecular flexibility. These features influence nearly every aspect of ADME performance, including permeability, solubility, plasma protein binding, and metabolic stability.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
At the same time, PROTACs do not behave like biologics or peptide therapeutics. Instead, they occupy a hybrid chemical space that blurs the line between small molecules and more complex therapeutic platforms. This creates a fundamental challenge for drug developers: standard ADME assays may technically generate data, but those data may not accurately reflect in vivo behavior unless the assays are specifically engineered for PROTAC properties.
For example, high lipophilicity can increase non-specific binding to plastics, membranes, and assay components, artificially reducing measured free concentrations. Slow diffusion kinetics can prevent equilibrium from being reached during standard assay timelines. In addition, the bifunctional structure of PROTACs introduces multiple metabolic liabilities that may not be captured through simplified screening systems.
These challenges underscore why traditional ADME “plug-and-play” workflows often fail to provide meaningful translational insight for targeted protein degraders.
LogP Determination Requires Experimentation
Lipophilicity is among the most influential physicochemical properties affecting PROTAC developability. LogP impacts permeability, solubility, plasma protein binding, tissue distribution, and formulation strategy. However, determining LogP accurately for PROTACs is far from straightforward. In silico prediction tools, while useful for conventional small molecules, often struggle with the size, flexibility, and unusual physicochemical properties. Computational models may substantially underestimate or overestimate lipophilicity because they were not trained on molecules with similar characteristics. Traditional shake-flask methods also present practical limitations. PROTACs frequently exhibit poor aqueous solubility, slow equilibration, and adsorption to experimental surfaces, all of which can compromise reproducibility and accuracy.
As a result, many researchers are turning to alternative analytical approaches such as reverse-phase high-performance liquid chromatography (RP-HPLC), which is often better suited for PROTAC programs. RP-HPLC methods can evaluate compounds across a broad LogP range with greater speed and reproducibility while reducing challenges associated with poor solubility and non-specific binding. Experimental optimization remains essential, however, because chromatographic conditions must still account for the unique retention behavior of these highly lipophilic, multifunctional molecules.
Even then, measuring lipophilicity alone does not tell the full story. Depending on their environment, PROTACs may demonstrate high LogP values yet still exhibit dynamic changes that alter exposed polarity and membrane interactions. Additional descriptors such as experimental polar surface area (EPSA) are increasingly being incorporated into early-stage screening to better predict permeability behavior.
Permeability Assessment Is an Assay Engineering Challenge
Permeability is another area where standard methodologies frequently generate misleading results for PROTACs. Standard permeability assays were designed for smaller, more soluble molecules, yet PROTACs typically dissolve better in acidic or biorelevant media such as FeSSIF and FaSSIF than in standard neutral pH transport buffers. This means conventional assays may underestimate exposure potential.
Highly lipophilic PROTACs also tend to bind non-specifically to plastics, filters, and cell membranes, reducing the amount of compound available for transport. Adding 1% bovine serum albumin (BSA) to transport buffers can help improve solubility and reduce these binding artifacts.
Slow equilibration presents another issue when assessing permeability. For PROTACs with LogP values above 5, intracellular concentrations may require 20–24 hours to reach steady state. Shorter assay timelines can therefore produce artificially low permeability values and inconsistent data.
Together, these factors make PROTAC permeability testing less of a standard screening exercise and more of an assay engineering challenge requiring customized experimental design.
High Protein Binding Complicates PK Interpretation
Many PROTACs exhibit extensive plasma protein binding (PPB), which can complicate pharmacokinetic interpretation. While high PPB is not necessarily problematic, inaccurate measurement of the unbound drug fraction can distort clearance predictions, exposure estimates, and PK/PD relationships.
As a result, traditional equilibrium dialysis methods may not be the best choice for PROTACs because slow equilibration and non-specific binding can interfere with accurate measurements. Highly lipophilic compounds may also stick to assay membranes or equipment, leading to underestimation of free-drug concentrations.
Alternative approaches, such as ultracentrifugation and flux dialysis, can help reduce these issues by minimizing membrane interference and improving equilibration control. Accurate free-drug measurement is especially important for PROTACs because intracellular target engagement ultimately drives therapeutic activity.
Metabolic Stability Requires Multi-System Assessment
Traditional microsomal stability assays alone rarely provide a complete picture of PROTAC metabolism. Their bifunctional structures introduce multiple metabolic hotspots across the target ligand, linker region, and E3 ligase recruiter. As a result, comprehensive characterization typically requires evaluation across multiple in vitro systems.
Liver microsomes are commonly used to evaluate cytochrome P450 metabolism, while hepatocytes help assess more complex processes involving transporters and phase II enzymes. Additional systems, such as liver or intestinal S9 fractions, as well as blood and plasma stability studies, are often needed to better understand biotransformation pathways and circulating stability.
Linker-derived metabolites are especially important because they may retain biological activity, contribute to off-target effects, or alter PK/PD relationships. As with other ADME assays, minimizing non-specific binding is critical to avoid inaccurate clearance predictions and improve in vitro–in vivo correlation.
A Final Word
As PROTAC pipelines continue to expand, the limitations of traditional ADME approaches are becoming increasingly apparent. These molecules occupy a unique chemical space that demands tailored analytical strategies, customized assays, and careful interpretation of pharmacokinetic data. Getting PROTAC development right requires more than incremental adjustments. It demands workflows that are designed around the distinct behavior of targeted protein degraders. Organizations that invest in these specialized capabilities will be better positioned to generate reliable translational data, improve candidate selection, and ultimately accelerate the successful development of this promising therapeutic class.
